论文部分内容阅读
HER2 is expressed or amplified in about 25% of breast cancers (BC), and is associated with an aggressive clinical course, and a poor overall prognosis. Although HER2- targeted therapy (i.e., trastuzumab) shows significantly improved survival in HER2-posit